761 related articles for article (PubMed ID: 11193242)
1. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
3. [New paradigms in the regulation of bone metabolism].
Rosa-Rañal M; de la Cruz DA; Lorena-Rubio Y; Larrea F
Rev Invest Clin; 2001; 53(4):362-9. PubMed ID: 11599485
[TBL] [Abstract][Full Text] [Related]
4. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
5. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
6. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Ann N Y Acad Sci; 2006 Apr; 1068():225-33. PubMed ID: 16831922
[TBL] [Abstract][Full Text] [Related]
7. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
8. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
Mochizuki S; Kiyokawa A; Nagayama Y
Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
[TBL] [Abstract][Full Text] [Related]
9. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.
Suda T; Takahashi N; Udagawa N; Jimi E; Gillespie MT; Martin TJ
Endocr Rev; 1999 Jun; 20(3):345-57. PubMed ID: 10368775
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
11. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
12. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
Takahashi N; Udagawa N; Suda T
Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
[TBL] [Abstract][Full Text] [Related]
13. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
[TBL] [Abstract][Full Text] [Related]
14. A novel molecular mechanism modulating osteoclast differentiation and function.
Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Goto M; Mochizuki SI; Tsuda E; Morinaga T; Udagawa N; Takahashi N; Suda T; Higashio K
Bone; 1999 Jul; 25(1):109-13. PubMed ID: 10423033
[TBL] [Abstract][Full Text] [Related]
15. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin and inflammation.
Saidenberg Kermanac'h N; Bessis N; Cohen-Solal M; De Vernejoul MC; Boissier MC
Eur Cytokine Netw; 2002; 13(2):144-53. PubMed ID: 12101070
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
Hofbauer LC; Schoppet M
JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
[TBL] [Abstract][Full Text] [Related]
18. [Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent].
Andelković Z; Katić V; Mihajlović D; Zivković V; Petrović A; Lalosević D
Med Pregl; 2005; 58(7-8):362-7. PubMed ID: 16296579
[TBL] [Abstract][Full Text] [Related]
19. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.
Gori F; Hofbauer LC; Dunstan CR; Spelsberg TC; Khosla S; Riggs BL
Endocrinology; 2000 Dec; 141(12):4768-76. PubMed ID: 11108292
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
Kostenuik PJ
Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]